The Economic Costs of Non‐ Communicable Diseases in The

The Economic Costs of Non‐ Communicable Diseases in The

THE ECONOMIC COSTS OF NON‐ Final Report COMMUNICABLE November 2012. DISEASES IN THE PACIFIC ISLANDS. A Rapid Stocktake of the situation in Samoa, Tonga and Vanuatu Exchange Rates Exchange rates at 30 June 2012 1 Samoan Tala = US$0.41 1 US$ = Samoan Tala 2.41 1 Tongan Pa’anga (TOP) = US$0.55 1 $US = Tongan Pa’anga (TOP) 1.79 1 Vanuatu Vatu (Vt) = US$0.0107 1 $US = Vanuatu Vatu (Vt) 93 Currency in $ All $ are current United States dollars, unless otherwise specified Page | i Table of Contents Acknowledgements ................................................................................................................................ iv Abbreviations .......................................................................................................................................... v Executive Summary ................................................................................................................................ vi Chapter One: context and purpose of this report .................................................................................. 1 NCDs as an international development issue ..................................................................................... 1 Why NCDs are a development challenge in the South Pacific ............................................................ 2 The objective, intended audience and status of this report ............................................................... 3 Definitional issues and data limitations in estimating financial and economic costs of NCDs in this report .................................................................................................................................................. 4 Chapter Two: the overall country context in Samoa, Tonga and Vanuatu ............................................. 7 Economies and per capita income ...................................................................................................... 9 Population and age structure ........................................................................................................... 10 Health indicators ............................................................................................................................... 10 Health financing ................................................................................................................................ 10 Chapter Three: Update on NCDs prevalence and risk factors in the Pacific ........................................ 12 Prevalence of NCDs in Samoa, Tonga and Vanuatu .......................................................................... 12 NCDs as the major cause of death ................................................................................................ 12 The role of cardiovascular disease ................................................................................................ 14 High rates of premature NCD deaths ............................................................................................ 15 Specific country data on NCDs ...................................................................................................... 17 Underlying Risk Factors for NCDs ..................................................................................................... 17 Obesity and overweight ................................................................................................................ 18 Changing diets ............................................................................................................................... 20 Physical inactivity and urbanisation .............................................................................................. 20 Tobacco and alcohol use ............................................................................................................... 21 Combined risk factors ................................................................................................................... 22 Type 2 Diabetes: a particularly significant NCD in the Pacific .......................................................... 25 Country responses to NCDs .............................................................................................................. 27 Chapter Four: Financial and Economic costs of NCDs. ......................................................................... 30 Recent estimates of the costs of NCDs from the international literature ........................................ 30 Estimating economic costs of NCDs in the Pacific. ........................................................................... 31 Estimating costs through National Health Accounts .................................................................... 31 Previous estimates of costs of NCDs. ............................................................................................. 33 Page | ii Previous studies on the costs of treating Type 2 diabetes in Vanuatu ......................................... 36 New estimates of the cost of drug treatment for diabetes and hypertension in Vanuatu .......... 37 New estimates of the cost of kidney dialysis in Samoa ................................................................ 38 Overseas Treatment Costs ............................................................................................................ 39 Chapter Five: Broad implications for Ministers of Health, and Ministers of Finance and Planning ..... 40 Implications for Ministers of Health ................................................................................................. 40 Implications for Ministers of Finance, and Planning, and their Ministries. ...................................... 42 Implications for both Ministers of Health, and Ministers of Finance: a convergence of public health and public expenditure and possible “win wins”.............................................................................. 51 Chapter 6: Initial Recommendations and Possible Next Steps ............................................................. 54 Initial recommendations for discussion with Governments and development partners. ................ 54 Possible next steps ............................................................................................................................ 56 Annex One: Pacific Islands Indicators of Non‐Communicable Diseases and Risk Factors in 2008 ....... 57 Annex Two: Health expenditure statistics for Samoa, Tonga and Vanuatu, 2010 ............................... 58 Annex Three: Health Expenditure Samoa, Tonga and Vanuatu compared to Income Groups ............ 59 Annex Four: Crude death rates from Non‐Communicable Diseases in the Pacific Island region ......... 60 Annex Five: Recent estimates of the economic costs of NCDs from the international literature ........ 61 Annex Six: Financial Cost to Government of Samoa of the National Kidney Foundation .................... 65 Annex Seven: First draft of a possible policy briefing note for a hypothetical Pacific Minister of Health, and Minister of Finance ............................................................................................................ 73 References ............................................................................................................................................ 75 Page | iii Acknowledgements This report was prepared by Ian Anderson, independent consultant, under the direction of Dr Eva Jarawan, Lead Health Specialist, East Asia and Pacific Region, The World Bank, and Task Team Leader for this project. Helpful comments and inputs were received on earlier drafts from several sources. Senior staff of The World Bank including S Chao, S Ivatts, J Langenbrunner, P Marquez, T Palu, and A Yazbeck made numerous constructive suggestions. M Lee of the World Bank assisted in finalization of the report. Helpful comments were also received from C Bell, J McKenzie, and T Waqanivalu of the World Health Organisation, and W Snowdon of Deakin University. Consultations were held with senior Government officials, and their development partners, in Samoa, Tonga and Vanuatu during October 2012 that generated valuable comments and suggestions. This analysis and report were made possible through financial support provided by the Government of Australia and the Government of New Zealand. Such support is greatly appreciated. Page | iv Abbreviations ALOS Average Length of Stay (in days, in a hospital) BMI Body Mass Index. A measure of weight for height, calculated as a person’s weight in kilograms divided by the square of the persons height in metres: kg/m2. WHO define BMI equal to or greater than 25 as overweight, and BMI equal to or greater than 30 as obese. There is ongoing research about how appropriate these cut off points are in the Pacific. COPD Chronic Obstructive Pulmonary Disease (i.e. respiratory and lung disease) CVD Cardiovascular disease ICD‐10 International Classification of Disease, 10th series. IDF International Diabetes Federation NKF National Kidney Foundation of Samoa MNCH Maternal, newborn and child health. NCDs Non‐communicable diseases (see box one) NHA National Health Account OPD Outpatient Department of a hospital PEN Package of Essential Non‐communicable (PEN) Disease Interventions for Primary Health Care in Low Resource Settings. (And initiative of the WHO) SAT Samoan Tala SNAP Smoking, Nutrition, Alcohol, Physical inactivity SPC Secretariat for the Pacific Community STEPS Not an acronym. It is the term used for the WHO stepwise approach

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    89 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us